Tom Vink

4.8k total citations · 2 hit papers
34 papers, 3.6k citations indexed

About

Tom Vink is a scholar working on Radiology, Nuclear Medicine and Imaging, Hematology and Molecular Biology. According to data from OpenAlex, Tom Vink has authored 34 papers receiving a total of 3.6k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Radiology, Nuclear Medicine and Imaging, 16 papers in Hematology and 8 papers in Molecular Biology. Recurrent topics in Tom Vink's work include Monoclonal and Polyclonal Antibodies Research (17 papers), Platelet Disorders and Treatments (12 papers) and Blood groups and transfusion (9 papers). Tom Vink is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (17 papers), Platelet Disorders and Treatments (12 papers) and Blood groups and transfusion (9 papers). Tom Vink collaborates with scholars based in Netherlands, Germany and United States. Tom Vink's co-authors include Paul W.H.I. Parren, Jan G. J. van de Winkel, Wim K. Bleeker, Jerry W. Slootstra, Janine Schuurman, Matthias Peipp, Thomas Valerius, Tamara H. den Bleker, Rob C. Aalberse and Mario Losen and has published in prestigious journals such as Science, Proceedings of the National Academy of Sciences and Journal of Clinical Oncology.

In The Last Decade

Tom Vink

34 papers receiving 3.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors

2010 746 citations Tom Vink, Matthias Peipp et al. The Journal of Immunology profile →
Anti-Inflammatory Activity of Human IgG4 Antibodies by Dynamic Fab Arm Exchange

2007 707 citations Janine Schuurman, Mario Losen et al. profile →

Peers

Countries citing papers authored by Tom Vink

Since Specialization

Citations

This map shows the geographic impact of Tom Vink's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tom Vink with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tom Vink more than expected).

Fields of papers citing papers by Tom Vink

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tom Vink. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tom Vink. The network helps show where Tom Vink may publish in the future.

Co-authorship network of co-authors of Tom Vink

This figure shows the co-authorship network connecting the top 25 collaborators of Tom Vink. A scholar is included among the top collaborators of Tom Vink based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tom Vink. Tom Vink is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Hinge-deleted IgG4 blocker therapy for acetylcholine receptor myasthenia gravis in rhesus monkeys 2017 ·Scientific Reports ·Mario Losen, Aran F. Labrijn, Vivianne van Kranen-Mastenbroek, Maarten L. Janmaat, Krista G. Haanstra, Frank J. Beurskens, Tom Vink, Margreet Jonker, Bert A. ‘t Hart, Marina Mané-Damas, Peter Molenaar, Pilar Martínez‐Martínez, (unknown), Janine Schuurman, Marc H. De Baets, Paul W.H.I. Parren	8
2	Efficient Payload Delivery by a Bispecific Antibody–Drug Conjugate Targeting HER2 and CD63 2016 ·Molecular Cancer Therapeutics ·Bart E.C.G. de Goeij, Tom Vink, (unknown), Esther C.W. Breij, David Satijn, Richard Wubbolts, David Miao, Paul W.H.I. Parren	101
3	HER2 monoclonal antibodies that do not interfere with receptor heterodimerization-mediated signaling induce effective internalization and represent valuable components for rational antibody-drug conjugate design 2014 ·mAbs ·Bart E.C.G. de Goeij, Matthias Peipp, Simone de Haij, Edward N. van den Brink, Christian Kellner, Thilo Riedl, Rob N. de Jong, Tom Vink, Kristin Strumane, Wim K. Bleeker, Paul W.H.I. Parren	22
4	Mutation of Y407 in the CH3 domain dramatically alters glycosylation and structure of human IgG 2013 ·mAbs ·Rebecca Rose, Patrick H.C. van Berkel, Ewald T.J. van den Bremer, Aran F. Labrijn, Tom Vink, Janine Schuurman, Albert J. R. Heck, Paul W.H.I. Parren	53
5	A simple, robust and highly efficient transient expression system for producing antibodies 2013 ·Methods ·Tom Vink, (unknown), Marcel Roza, (unknown), Rob N. de Jong	102
6	Crosstalk between Human IgG Isotypes and Murine Effector Cells 2012 ·The Journal of Immunology ·Marije B. Overdijk, Sandra Verploegen, Antonio Ortiz Buijsse, Tom Vink, Jeanette H.W. Leusen, Wim K. Bleeker, Paul W.H.I. Parren	157
7	Rapid production of recombinant human IgG With improved ADCC effector function in a transient expression system 2009 ·Biotechnology and Bioengineering ·Patrick H.C. van Berkel, (unknown), (unknown), Gerrard J. Perdok, Tom Vink, Jan G. J. van de Winkel, Paul W.H.I. Parren	33
8	N‐linked glycosylation is an important parameter for optimal selection of cell lines producing biopharmaceutical human IgG 2009 ·Biotechnology Progress ·Patrick H.C. van Berkel, (unknown), Gerrard J. Perdok, (unknown), Tom Vink, Jan G. J. van de Winkel, Paul W.H.I. Parren	62
9	Antibody fucosylation differentially impacts cytotoxicity mediated by NK and PMN effector cells 2008 ·Blood ·Matthias Peipp, Jeroen J. Lammerts van Bueren, Tanja Schneider‐Merck, (unknown), Michael Dechant, Thomas Beyer, Roland Repp, Patrick H.C. van Berkel, Tom Vink, Jan G. J. van de Winkel, Paul W.H.I. Parren, Thomas Valerius	169
10	The Biological Activity of Human CD20 Monoclonal Antibodies Is Linked to Unique Epitopes on CD20 2006 ·The Journal of Immunology ·Jessica L. Teeling, Wendy J.M. Mackus, (unknown), (unknown), Stephen A. Beers, Ruth R. French, Tom van Meerten, Saskia B. Ebeling, Tom Vink, Jerry W. Slootstra, Paul W.H.I. Parren, Martin J. Glennie, Jan G. J. van de Winkel	466
11	Melanocortin System and Eating Disorders 2003 ·Annals of the New York Academy of Sciences ·Roger A.H. Adan, Jacquelien J Hillebrand, (unknown), Wouter A.J. Nijenhuis, Tom Vink, Keith M. Garner, Martien J. Kas	25
12	Association between an agouti-related protein gene polymorphism and anorexia nervosa 2001 ·Molecular Psychiatry ·Tom Vink, Anke Hinney, Annemarie Elburg, Stephanie H.M. van Goozen, Lodewijk A. Sandkuijl, Richard J. Sinke, (unknown), Johannes Hebebrand, Helmut Remschmidt, Hermán van Engeland, R.A.H. Adan	132
13	Drug target discovery by pharmacogenetics: mutations in the melanocortin system and eating disorders 2001 ·European Neuropsychopharmacology ·Roger A.H. Adan, Tom Vink	20
14	von Willebrand Factor without the A2 Domain Is Resistant to Proteolysis 1997 ·Thrombosis and Haemostasis ·H. Lankhof, (unknown), Marion E. Schiphorst, Martin J. W. IJsseldijk, Madelon Bracke, Miha Furlan, Han‐Mou Tsai, Philip G. de Groot, Jan J. Sixma, Tom Vink	24
15	Functional Studies on Platelet Adhesion With Recombinant von Willebrand Factor Type 2B Mutants R543Q and R543W Under Conditions of Flow 1997 ·Blood ·H. Lankhof, (unknown), Marion E. Schiphorst, Martin J. W. IJsseldijk, Madelon Bracke, Jan J. Sixma, Tom Vink, Philip G. de Groot	29
16	A3 Domain Is Essential for Interaction of von Willebrand Factor with Collagen Type III 1996 ·Thrombosis and Haemostasis ·H. Lankhof, (unknown), Marion E. Schiphorst, Madelon Bracke, Yaping Wu, Martin J. W. IJsseldijk, Tom Vink, Philip G. de Groot, Jan J. Sixma	121
17	Requirements of von Willebrand factor to protect factor VIII from inactivation by activated protein C 1996 ·Blood ·SJ Koppelman, (unknown), Tom Vink, H. Lankhof, (unknown), (unknown), (unknown), Robert A. Wise, BN Bouma, JJ Sixma	42
18	Role of the glycoprotein Ib-binding A1 repeat and the RGD sequence in platelet adhesion to human recombinant von Willebrand factor 1995 ·Blood ·H. Lankhof, (unknown), Tom Vink, (unknown), Hans‐Günter Zerwes, PG de Groot, JJ Sixma	59
19	Tissue Factor Expression on Mesothelial Cells is Induced during in vitro Culture – Manipulation of Culture Conditions Creates Perspectives for Mesothelial Cells as a Source for Cell Seeding Procedures on Vascular Grafts 1995 ·Thrombosis and Haemostasis ·Hence J.M. Verhagen, (unknown), Tom Vink, Apollo Pronk, Theo J. M. V. van Vroonhoven, B.C. Eikelboom, Jan J. Sixma, Philip G. de Groot	22
20	Mutants of the elongation factor EF-Tu, a new class of nonsense suppressors. 1985 ·The EMBO Journal ·Erik Vijgenboom, Tom Vink, Barend Kraal, Ludo Van Den Bosch	71

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact